SCHEMBL4160754

SCHEMBL4160754

Cc1nc(-c2ccc(Br)s2)cs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.54
POLB P06746 3/20 0.54
LMNA P02545 2/20 0.54
ABL1 P00519 1/20 0.54
MAPT P10636 7/20 0.47
ALDH1A1 P00352 4/20 0.47
HSD17B10 Q99714 3/20 0.47
NPC1 O15118 2/20 0.47
GFER P55789 1/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
RXFP1 Q9HBX9 3/20 0.44
PRNP P04156 1/20 0.44
PPARG P37231 2/20 0.43
NCOA2 Q15596 2/20 0.43
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL423483 0.82 MAPT (0.68) KDM4EPOLBMAPTALDH1A1HSD17B10
SCHEMBL3418282 0.78 MAPT (0.63) KDM4EPOLBLMNAABL1MAPT
SCHEMBL29152951 0.77 KDM4E (0.66) KDM4EPOLBLMNAABL1MAPT
SCHEMBL13108779 0.74 KDM4E (0.46) KDM4EPOLBMAPTALDH1A1HSD17B10
SCHEMBL10211630 0.74 KDM4E (0.46) KDM4EPOLBMAPTALDH1A1HSD17B10
SCHEMBL24359598 0.73 GAA (0.52) KDM4EPOLBMAPTALDH1A1HSD17B10
SCHEMBL3823188 0.73 KDM4E (0.48) KDM4EPOLBMAPTALDH1A1HSD17B10
SCHEMBL3074282 0.73 KDM4E (0.48) KDM4EPOLBMAPTALDH1A1HSD17B10
SCHEMBL15008586 0.73 KDM4E (0.48) KDM4EPOLBMAPTALDH1A1HSD17B10
SCHEMBL14188119 0.73 KDM4E (0.48) KDM4EPOLBMAPTALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
EP-1951244-A2 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed
CN-1343215-A 6-O-substituted macrolides with antibacterial activity ABBOTT LAB (US) 2002-04-03 CN disclosed
EP-1161438-A1 6-O-SUBSTITUTED MACROLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 2001-12-12 EP disclosed
WO-2000055168-A1 6-O-SUBSTITUTED MACROLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 2000-09-21 WO disclosed
US-6054435-A 6-O-substituted macrolides having antibacterial activity ABBOTT LABORATORIES (US) 2000-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB KDM4E 4712/4885POLB 1810/4885LMNA 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.